Home / Healthcare/ 3M to buy medical device maker Acelity in $ 6.7 b deal

3M to buy medical device maker Acelity in $ 6.7 b deal

Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 7 May 2019 00:00


Reuters: 3M Co said yesterday it would buy privately held medical device maker Acelity Inc in a deal valued at $ 6.7 billion, including debt, as the US industrial conglomerate looks to expand its business in medical dressings and related products. 

The maker of Post-It notes and Scotch tape is buying the company and some of its units from a consortium of funds advised by Apax Partners, affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board. 

Acelity, under its KCI brand, makes advanced wound dressings and specialised systems that use a vacuum to seal off acute or chronic wounds, promoting faster healing. 

The company reported revenue of $ 1.5 billion in 2018, nearly 80% of which came from sales of such specialised systems that provide ‘negative pressure wound therapy’. 

3M said the acquisition would boost its presence in the advanced wound care market, which is valued at more than $ 8 billion and is growing at a rate of 4-6% annually. 

The purchase price values Acelity at 15 times its 2018 adjusted earnings before interest, tax, depreciation and amortisation, 3M said. 

Acelity will become part of 3M’s medical solutions business that makes medical tapes, sterilisation products and acute wound care dressings products. The deal is expected to close in the second half of 2019. 

Excluding one-time expenses, 3M expects the deal to add 25 cents per share to its earnings in the first year following the closure of the deal. 

3M also said it now expects full-year 2019 share buyback program to be in the range of $ 1 billion to $ 1.5 billion, compared with a prior range of $ 2 billion to $ 4 billion. 

The company’s stock was down about 1% at $ 184.23 before the bell. 

Credit Suisse was financial adviser to 3M, while Cleary Gottlieb Steen & Hamilton LLP was its legal counsel. 

J.P. Morgan and Goldman Sachs were the consortium’s financial advisers, with Simpson Thacher & Bartlett LLP and Jackson Walker LLP acting as its legal advisers.

Share This Article

Facebook Twitter


1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.


Today's Columnists

17 things ‘Avengers: Endgame’ teaches us about the state of our superheroes

Friday, 24 May 2019

Art imitates life. Even movies do. Maybe especially so. In these lean times, there’s nothing like a little laughter to stop the press, stem the blood pressure, ease that stress in life. So here goes. Trust you’ll take these tongue-in-cheek. Or pe

Sri Lanka needs urgent surgery!

Friday, 24 May 2019

Sri Lanka was on the slippery slope of a serious crisis, heading for a great disaster of the State, even before the outbreak of Easter Sunday attacks. Now, in the aftermath of the ruthless Easter Sunday attacks, the country’s crisis has become exac

Mangala, Monks, Mangala Sutta and Marx

Friday, 24 May 2019

In the Buddhist belief system, ‘Mangala’ means a ‘blessing’. In the abstract ‘Mangala’ denotes an ‘auspicious sign’. In the ‘Mangala Sutta’, the Buddha has enumerated 38 of the highest blessings that we must or should be guided b

Who built the Matara/Beliatta railway line?

Friday, 24 May 2019

In 2019, after 70 long years of independence, Sri Lanka succeeded in adding to the rail network left behind by the British when we extended the southern line from Matara to Beliatta, a distance of less than 20 miles. While the network left in place b

Columnists More